Glaukos

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. 

CEO
Thomas William Burns
CEOThomas William Burns
Employees
1,094
Employees1,094
Headquarters
Aliso Viejo, California
HeadquartersAliso Viejo, California
Founded
1998
Founded1998
Employees
1,094
Employees1,094

GKOS Key Statistics

Market cap
9.46B
Market cap9.46B
Price-Earnings ratio
-49.11
Price-Earnings ratio-49.11
Dividend yield
Dividend yield
Average volume
834.92K
Average volume834.92K
High today
$178.00
High today$178.00
Low today
$171.10
Low today$171.10
Open price
$145.78
Open price$145.78
Volume
13.55K
Volume13.55K
52 Week high
$178.00
52 Week high$178.00
52 Week low
$73.16
52 Week low$73.16

Stock Snapshot

With a market cap of 9.46B, Glaukos(GKOS) trades at $176.00. The stock has a price-to-earnings ratio of -49.11.

As of 2026-07-30, Glaukos(GKOS) stock has fluctuated between $171.10 and $178.00. The current price stands at $176.00, placing the stock +2.9% above today's low and -1.1% off the high.

The Glaukos(GKOS)'s current trading volume is 13.55K, compared to an average daily volume of 834.92K.

During the past year, Glaukos(GKOS) stock moved between $73.16 at its lowest and $178.00 at its peak.

During the past year, Glaukos(GKOS) stock moved between $73.16 at its lowest and $178.00 at its peak.

GKOS News

TipRanks 2h
Glaukos Earns Reiterated Buy, Top Pick Rating as Strong Execution Drives Upward Price Target Revision to $193

Ryan Zimmerman, an analyst from BTIG, reiterated the Buy rating on Glaukos. The associated price target was raised to $193.00. Unlock powerful investing tools...

Investing.com 3h
Truist raises Glaukos stock price target to $215 on higher estimates - Investing.com

...

Truist raises Glaukos stock price target to $215 on higher estimates - Investing.com
TipRanks 16h
Glaukos Reports Record Q2 Sales, Raises 2026 Guidance

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Analyst ratings

93%

of 14 ratings
Buy
92.9%
Hold
7.1%
Sell
0%

More GKOS News

TipRanks 16h
Glaukos reports Q2 adjusted EPS (14c), consensus (21c)

Reports Q2 revenue $185.6M, consensus $150.91M. “Our record second quarter results reflect successful global execution across our key global commercial and deve...

People also own

Based on the portfolios of people who own GKOS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.